Cytokine Response in Septic Shock
1 other identifier
observational
325
1 country
1
Brief Summary
This study is designed to examine the early sequential cytokine responses during antibiotic therapy and resuscitation of septic shock in relation to clinical manifestations of disease. The specific objective is to obtain sequential serum samples from patients with septic shock, examine a broad range of cytokine responses (TNF, IL-1, IL-6, MIF, LIF, HMGB1, etc) in a rigorous manner and correlate these responses to administration of antibiotics, resuscitative efforts and physiologic responses to illness (temp, HR, blood pressure, WBC, etc).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedFirst Submitted
Initial submission to the registry
January 15, 2013
CompletedFirst Posted
Study publicly available on registry
January 17, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedJuly 25, 2013
July 1, 2013
7.8 years
January 15, 2013
July 24, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cytokine response in septic shock
his study is designed to examine the early sequential cytokine responses during antibiotic therapy and resuscitation of septic shock in relation to clinical manifestations of disease. The specific objective is to obtain sequential serum samples from patients with septic shock, examine a broad range of cytokine responses (TNF, IL-1, IL-6, MIF, LIF, HMGB1, etc) in a rigorous manner and correlate these responses to administration of antibiotics, resuscitative efforts and physiologic responses to illness (temp, HR, blood pressure, WBC, etc).
Hours 0, 3, 6, 12, 18, 24, 36, 48, 96 and day 7
Eligibility Criteria
All adult patients with septic shock admitted to intensive care units who are receiving vasopressors for septic shock for \<24 hrs. No significant exclusions exist.
You may qualify if:
- Adult ICU patients: . 18 years admitted with septic shock
- Receiving Vasopressors \< 24 hrs
You may not qualify if:
- Consent refused by patient or SDM
- Received Vasopressors \> 24hrs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Health Sciences Centre, Winnipeg
Winnipeg, Manitoba, R3A 1R9, Canada
Biospecimen
Serum samples will be collected at specific time points. Initial time point determined by start of Vasopressors Then sequential serum samples will be drawn from patients to examine a broad range of cytokine responses (TNF, IL-1, IL-6, MIF, LIF, HMGB1, etc)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anand Kumar, MD
University of Manitoba
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Attending physician/ investigator WRHA
Study Record Dates
First Submitted
January 15, 2013
First Posted
January 17, 2013
Study Start
April 1, 2006
Primary Completion
February 1, 2014
Study Completion
December 1, 2014
Last Updated
July 25, 2013
Record last verified: 2013-07